Brii Biosciences (2137.HK) released topline end-of-treatment data from its Phase 2b ENRICH and ENHANCE studies, advancing the clinical read-out on its chronic hepatitis B therapeutic programme.
Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results